Abstract 112P
Background
KEYNOTE-177 (NCT02563002) was a randomized, open-label phase III study of first-line (1L) pembrolizumab (P) vs chemotherapy (C) in patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). P significantly improved progression-free survival (PFS) vs C in KEYNOTE-177; the Asia subgroup (sg) analysis is presented.
Methods
Pts with previously untreated dMMR/MSI-H stage IV mCRC and an Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned 1:1 to P 200 mg every 3 weeks or investigator’s choice of C (mFOLFOX6/FOLFIRI every 2 weeks ± bevacizumab/cetuximab). Primary endpoints were PFS per Response Evaluation Criteria in Solid Tumors version 1.1 by central review and overall survival. Hazard ratio and 95% confidence interval of PFS were based on Cox regression model with Efron’s method of tie handling with treatment as a covariate. PFS and duration of response (DOR) were assessed per Kaplan-Meier analysis. Secondary endpoints were overall response rate (ORR) and safety. Confirmed responses are shown.
Results
Of 307 pts enrolled in the study, 153 were randomly assigned to P and 154 to C. Of the 307 pts, 48 were enrolled from Asia (P, n=22; C, n=26). At data cutoff (19 Feb 2020), median follow-up in the Asia sg was 28.7 mo in the P arm vs 23.3 mo in the C arm. Efficacy and safety in the total population (pop) and Asia sg are presented in the table.
Conclusions
1L P compared with C showed clinically meaningful improvement in PFS, led to more durable responses and improved safety profile in the total pop of pts with dMMR/MSI-H mCRC. The Asia sg results were generally consistent with those of the total pop of KEYNOTE-177 Table: 112P
P (total pop) | C (total pop) | P (Asia sg) | C (Asia sg) | |
ITT pop, n | 153 | 154 | 22 | 26 |
Median PFS, mo | 16.5 | 8.2 | NR | 10.4 |
HR (95% CI) | 0.60 (0.45-0.80) | -- | 0.65 (0.30-1.41) | -- |
12-mo PFS rate, % | 55.3 | 37.3 | 62.0 | 45.9 |
ORR, n (%) | 67 (43.8) | 51 (33.1) | 10 (45.5) | 12 (46.2) |
CR, n (%) | 17 (11.1) | 6 (3.9) | 2 (9.1) | 3 (11.5) |
PR, n (%) | 50 (32.7) | 45 (29.2) | 8 (36.4) | 9 (34.6) |
Median DOR, (range), mo | NR (2.3+-41.4+) | 10.6 (2.8-37.5+) | NR (4.4+-33.1+) | 28.8 (3.4+-35.5+) |
Response duration ≥24 mo, % | 82.6 | 35.3 | 87.5 | 51.1 |
APAT pop, n | 153 | 143 | 22 | 25 |
Any grade TRAE, n (%) | 122 (79.7) | 141 (98.6) | 14 (63.6) | 25 (100.0) |
Grade 3-5 TRAE, n (%) | 33 (21.6) | 94 (65.7) | 2 (9.1) | 20 (80.0) |
APAT, all patients as treated; NR, not reached; TRAE, treatment-related adverse event.
.Clinical trial identification
NCT02563002.
Editorial acknowledgement
Provided by Jemimah Walker, PhD, and Doyel Mitra, PhD, of the ApotheCom pembrolizumab team (Yardley, PA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
T. Yoshino: Research grant/Funding (institution): Taiho Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Amgen K.K., Parexel International Inc., MSD K.K., Daiichi Sankyo Co., Ltd., and Sanofi K.K. T.W. Kim: Research grant/Funding (institution): Research Grant/Funding (Institution) Merk Serono, AstraZeneca, Pfizer. W.P. Yong: Speaker Bureau/Expert testimony: Bayer. K-K. Shiu: Honoraria (self): BMS, Guardant Health, Innovent Biologics, Merck KGaA, Roche, Servier; Advisory/Consultancy: Roche; Research grant/Funding (institution): Amgen, BMS, Gilead, Merck KGaA, MSD, Roche; Travel/Accommodation/Expenses: MSD, Merck KGaA, Innovent Biologics. B. Vittrup Jensen: Research grant/Funding (institution): Merck Sharp & Dohme Corp. L. Henrik Jensen: Research grant/Funding (institution): MSD, 2cureX, Incyte, BMS. R. Garcia-Carbonero: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: AAA, Advanz Pharma, Bayer, BMS, HMP, Ipsen, Merck, Midatech Pharma, MSD, Novartis, PharmaMar, Pfizer, Pierre Fabre, Roche, Sanofi and Servier; Research grant/Funding (self): Pfizer, BMS; Research grant/Funding (institution): ARMO Biosciences, AstraZeneca, Pfizer, Novartis, Ipsen, Roche, Pharmacyclics, Boston Biomedicals, Merck, MSD, Amgen, Sanofi, Bayer, Bristol-Myers-Squibb, Boerhringer, Sysmex, Gilead Sciences, Servier, Adacap, VCN, Lilly, Pharmamar; Non-remunerated activity/ies: Member of the Executive Committee of the Spanish Neuroendocrine Tumor Cooperative Group (GETNE), Member of the Executive Committee of the European Society of Neuroendocrine Tumors (ENETS), Member of the Scientific Advisory Group for Oncology (SAG-O) of th; Non-remunerated activity/ies: Global PI of a clinical trial of Axitinib (Pfizer) in NETs; Global PI of a clinical trial of Nivolumab (BMS) and chemotherapy in NECs; Non-remunerated activity/ies: Member of the EORTC, ASCO, ESMO, SEOM, TTD, GEMCAD. J. Alcaide-Garcia: Speaker Bureau/Expert testimony: Amgen; Travel/Accommodation/Expenses: MSD, Merck, Roche, Sanofi, Bristol. P. Gibbs: Honoraria (self), Research grant/Funding (self): Merck. C. de la Fouchardiere: Advisory/Consultancy: Roche, Pierre Fabre Oncologie, MSD, Eisai, Bayer; Travel/Accommodation/Expenses: Amgen, Eisai, BMS, Roche. F. Rivera: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: MSD, Roche, Merck-Serono, Sanofi, BMS, Servier, Lilly, Amgen, Bayer, Celgene. E. Elez: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Hoffman La Roche, Sanofi Aventis, Amgen, Merck Serono, Servier, MSD, Array Pharmaceuticals, Bristol-Myers Squibb; Honoraria (institution): Hoffman La Roche, Sanofi Aventis, Amgen, Merck Serono, MSD, Boehringer Ingelheim, AbbVie, Array Pharmaceuticals, Pierre-Fabre, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Medimmune. J. Bendell: Research grant/Funding (institution): Gilead, Genentech/Roche, BMS, Five Prime, Lilly, Merck, MedImmune, Celgene, EMD Serono, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Koltan, SynDevRex, Forty Seven, AbbVie, Ar; Advisory/Consultancy: Gilead, Genentech/Roche, BMS, Five Prime, Lilly, Merck, MedImmune, Celgene, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Array, Sanofi, ARMO, Ipsen, Merrimack, Oncogenex, FORM; Travel/Accommodation/Expenses: Gilead, Genentech/Roche, BMS, Lilly, Merck, MedImmune, Celgene, Taiho, Novartis, OncoMed, BI, ARMO, Ipsen, Oncogenex, FORMA. D.T. Le: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck; Advisory/Consultancy, Research grant/Funding (institution): BMS; Research grant/Funding (institution): Aduro, Medivir, Curegenix, Nouscom; Licensing/Royalties: Patent pending: technology for mismatch repair deficiency. P. Yang: Full/Part-time employment: MSD China Holding Co., Ltd.. M. Farooqui: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc.. P. Marinello: Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc.. L.A. Diaz: Advisory/Consultancy: Personal Genome Diagnostics, 4Paws, Neophore; Leadership role: Jounce Therapeutics, Personal Genome Diagnostics; Shareholder/Stockholder/Stock options: Jounce Therapeutics, Personal Genome Diagnostics, 4Paws, Amgen, Thrive; Research grant/Funding (self), Non-remunerated activity/ies: Merck; Travel/Accommodation/Expenses: Jounce Therapeutics, Personal Genome Diagnostics, 4Paws, Merck, Neophore; Licensing/Royalties: Personal Genome Diagnostics, Thrive, Qiagen; Officer/Board of Directors: Jounce Therapeutics, Personal Genome Diagnostics. T. Andre: Honoraria (self): Bristol-Myers Squibb, Chugai, GSK, Pierre Fabre, Roche/Vantana, Sanofi, Servier ; Advisory/Consultancy: Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Gritstone Oncology, Halliodx, Merck Sharp & Dohme Corp, Pierre Fabre, Roche/Vantana, Sanofi, Servier, Tesaro; Speaker Bureau/Expert testimony: Bristol-Myers Squibb, Servier; Research grant/Funding (institution): Merck Sharp & Dohme Corp.; Travel/Accommodation/Expenses: Roche/Vantana, Merck Sharp & Dohme Corp, Bristol-Myers Squibb; Non-remunerated activity/ies: Participant to the Scientific committee of ARCAD Foundation and GERCOR Group. All other authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session